Which component is NOT assessed in the Triple Screen test?

The Triple Screen test is a blood test conducted in the second trimester of pregnancy to assess the risk of certain fetal conditions, notably Down syndrome and certain neural tube defects. The three primary components evaluated in this test are Alpha-fetoprotein (AFP), human Chorionic Gonadotropin (hCG), and Unconjugated Estriol, which are all markers that provide information about the pregnancy and fetal health.

Inhibin A, while it is an important biomarker, is not included in the traditional Triple Screen test, which is why identifying it as the answer is critical. Instead, Inhibin A is part of the Quad Screen test, which adds it to the mix of indicators for better risk assessment.

Understanding the components of these screening tests helps to clarify their purpose and limits, ensuring better-informed decisions during prenatal care.